Excellence in Single Domain Biotherapeutics
Isogenica develops therapeutic VHH:
highly versatile small format antibodies which we use to construct next generation biotherapeutics for the treatment of cancer, inflammation and other serious diseases.
News & Events
This edition we’re talking synthetic libraries: read on to see how we can save up to 8 months on immunisation alone compared with traditional approaches. Since November we’ve seen Dave attend Genesis in London, Ben go to PEGS, Barcelona, and Marion off to CAR-T, London….
Dave Mead our Director of Business Development is heading to ON Helix this July and we’re looking to find partners in the biotechnology space. ON...
Our Director of Business Development, Dave Mead recently attended BioEurope in Basel, meeting with colleagues old and new to discuss potential new...
Isogenica’s partnerships with global biopharmaceutical companies have resulted in a deep pipeline including one clinical Phase II asset and eleven partnered pre-clinical and discovery programs.
Isogenica works with partners through collaborative research and commercial licenses to further develop proprietary LlamdA® VHH or to discover novel LlamdA® VHH as direct therapeutics and targeting agents.
Careers at Isogenica
A career at Isogenica provides an opportunity to lead, execute or support the commercial development of next generation biotherapeutics.